These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19335278)

  • 1. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
    Gimsing P
    Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
    Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
    Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors: overview and perspectives.
    Dokmanovic M; Clarke C; Marks PA
    Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in cancer treatment with histone deacetylase inhibitor].
    Dong M; Hu XS; Chen SS; Xing PY; Feng FY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):481-5. PubMed ID: 24257296
    [No Abstract]   [Full Text] [Related]  

  • 6. Belinostat for the treatment of peripheral T-cell lymphomas.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

  • 8. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
    Qian X; Ara G; Mills E; LaRochelle WJ; Lichenstein HS; Jeffers M
    Int J Cancer; 2008 Mar; 122(6):1400-10. PubMed ID: 18027850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy.
    Witt O; Lindemann R
    Cancer Lett; 2009 Aug; 280(2):123-4. PubMed ID: 19303208
    [No Abstract]   [Full Text] [Related]  

  • 11. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
    Monks A; Hose CD; Pezzoli P; Kondapaka S; Vansant G; Petersen KD; Sehested M; Monforte J; Shoemaker RH
    Anticancer Drugs; 2009 Sep; 20(8):682-92. PubMed ID: 19606018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
    El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
    Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer.
    Hede K
    J Natl Cancer Inst; 2006 Mar; 98(6):377-9. PubMed ID: 16537828
    [No Abstract]   [Full Text] [Related]  

  • 14. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Rashidi A; Cashen AF
    Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belinostat: clinical applications in solid tumors and lymphoma.
    Molife LR; de Bono JS
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belinostat: first global approval.
    Poole RM
    Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors: a review on class-I specific inhibition.
    Behera J; Jayaprakash V; Sinha BN
    Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorinostat approved for rare lymphoma.
    Thompson CA
    Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
    Atadja P
    Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.